Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.

Allogeneic hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-matched related donors (RDs) and allogeneic HCT using HLA-matched unrelated donors (URDs) produce similar outcomes for patients with acute myelogenous leukemia, whereas the donor source has been reported to be a predictor of outcomes in myelodysplastic syndrome. Post-HCT outcomes for 1458 acute lymphoblastic leukemia patients from 2000 to 2011 were analyzed, and RD and URD transplants were compared. The median age was 37 years (range, 18-69 years). In the multivariate analysis, HLA 8/8 allele-matched URD recipients had similar transplant-related mortality (TRM) and all-cause mortality in comparison with RD recipients (hazard ratios [HRs], 1.16 [95% confidence interval (CI), 0.91-1.48] and 1.01 [95% CI, 0.85-1.19], respectively); 7/8 URD recipients had a greater risk of TRM and all-cause mortality in comparison with RD recipients (HRs, 1.92 [95% CI, 1.47-2.52] and 1.29 [95% CI, 1.05-1.58], respectively). The risk of TRM and all-cause mortality was also greater for 7/8 URD recipients versus 8/8 URD recipients. Compared with RD recipients, both 8/8 and 7/8 URD recipients had a lower risk of relapse (HRs, 0.77 [95% CI, 0.62-0.97] and 0.75 [95% CI, 0.56-1.00], respectively). Both 8/8 and 7/8 URD recipients had a greater risk of acute graft-versus-host disease (GVHD; HRs, 2.18 [95% CI, 1.76-2.70] and 2.65 [95% CI, 2.06-3.42], respectively) and chronic GVHD (HRs, 1.28 [95% CI, 1.06-1.55] and 1.46 [95% CI, 1.14-1.88], respectively) in comparison with RD recipients. In the absence of RD transplantation, 8/8 URD transplantation is a viable alternative with similar survival outcomes, whereas 7/8 URD transplantation is associated with poorer overall survival. Cancer 2017;123:3346-55. © 2017 American Cancer Society.

Segal E ，Martens M ，Wang HL ，Brazauskas R ，Weisdorf D ，Sandmaier BM ，Khoury HJ ，de Lima M ，Saber W ... -  《-》

Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

Tomblyn MB ，Arora M ，Baker KS ，Blazar BR ，Brunstein CG ，Burns LJ ，DeFor TE ，Dusenbery KE ，Kaufman DS ，Kersey JH ，MacMillan ML ，McGlave PB ，Miller JS ，Orchard PJ ，Slungaard A ，Tomblyn MR ，Vercellotti GM ，Verneris MR ，Wagner JE ，Weisdorf DJ ... -  《-》

Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.

Weisdorf DJ ，Nelson G ，Lee SJ ，Haagenson M ，Spellman S ，Antin JH ，Bolwell B ，Cahn JY ，Cervantes F ，Copelan E ，Gale R ，Gratwohl A ，Khoury HJ ，McCarthy P ，Marks DI ，Szer J ，Woolfrey A ，Cortes-Franco J ，Horowitz MM ，Arora M ，Chronic Leukemia Working Committee ... -  《-》

Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors.

Smith AR ，Baker KS ，Defor TE ，Verneris MR ，Wagner JE ，Macmillan ML ... -  《-》

Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.

Kumar P ，Defor TE ，Brunstein C ，Barker JN ，Wagner JE ，Weisdorf DJ ，Burns LJ ... -  《-》